ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

Kyprolis Demonstrates Overall Response Following FDA Accelerated Approval

August 31, 2012

VP Bush Visits NIH To Learn About AIDS

April 17, 1987

Matrisian, Nelson, to lead review of NCI translational research programs.

September 23, 2005

NCI Provides $40 Million To Four Centers For Cancer Communications Research.

June 27, 2003

FDA Approves Afinitor For pNET; No Word On Sutent For Same Use

May 6, 2011

NCS Heeds Bloch’s Plea, To Consider Establishing Separate PDQ-Like System For General Public Use

December 7, 1984